IP Verse

Novel Pharmaceutical Formulation Comprising Dual Nk-1/Nk-3 Receptor Antagonists

Patent No. EP3765024 (titled "Novel Pharmaceutical Formulation Comprising Dual Nk-1/Nk-3 Receptor Antagonists") was filed by Kandy Therapeutics on Mar 13, 2019. The application was issued on Nov 22, 2023.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
AERAAug 5, 2024AERA
AERAAug 5, 2024BARDEHLE PAGENBERG SL

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3765024

KANDY THERAPEUTICS
Application Number
EP19711866A
Filing Date
Mar 13, 2019
Status
Granted And Under Opposition
Oct 20, 2023
Publication Date
Nov 22, 2023
External Links
Slate, EP3765024B1, Google Patents